This is the question we hear most often: tirzepatide or retatrutide? Both are incretin peptides. Both demonstrate serious weight reduction in trials. But they work differently under the hood, and the choice depends on what matters more to you: proven data or cutting-edge mechanism.

The core difference

[[Tirzepatide|10]] activates two receptors: GLP-1 and GIP. [[Retatrutide|11]] activates three: GLP-1, GIP, and glucagon.

That third receptor is what makes retatrutide interesting. Glucagon receptor activation increases resting energy expenditure (you burn more calories doing nothing) and ramps up fat oxidation in the liver. Tirzepatide doesn't do this. Neither does semaglutide.

But more mechanisms also means less data so far. And that's the tradeoff.

Tirzepatide: the proven option

Multiple completed Phase III trials. Thousands of participants. Published in NEJM.

• SURMOUNT-1 (2022, 2539 people): metabolic changes at 15mg over 72 weeks
• SURPASS-2 (2021, 1879 people): beat semaglutide 1mg at every dose level
• HbA1c drops of 2.0-2.5 percentage points in diabetic populations

The safety profile is well-documented. We know the side effects, the titration sweet spots, the long-term outcomes. If you want a compound with a thick evidence binder behind it, tirzepatide is that compound.

Retatrutide: the aggressive newcomer

Phase II data published in NEJM, 2023. 338 participants, 48 weeks.

• Highest dose group: That's faster and deeper than tirzepatide at the same timepoint. But it's a smaller study, earlier stage. Phase III needs to confirm these numbers in thousands of people, not hundreds.

  Side effects

  Both cause GI issues during titration. Nausea, diarrhea, vomiting. Standard GLP-1 territory. Fades with time if you titrate properly.

  Retatrutide adds one wrinkle: the glucagon component can bump heart rate slightly (5-10 bpm increase in some trial participants). It also affects blood glucose differently than a pure GLP-1 agonist, though the GLP-1/GIP activity balances this out in practice. These glucagon-specific effects are still being characterized in ongoing Phase III work.

  Neither peptide showed serious safety signals. But tirzepatide simply has a bigger safety dataset because it's been studied longer in larger trials.

  Dosing and formats

  Both are weekly subcutaneous injections with similar titration schedules (start low, increase monthly).

  Tirzepatide: [[Tirzepatide|10]] vials (10/30/60mg) or [[Tirzepatide pen|36]] pens (30/60mg).

  Retatrutide: [[Retatrutide|11]] vials (10/30/60mg) or [[Retatrutide Pen|38]] pens (30/60mg).

  Reconstitution, storage, injection technique are identical for both.

  How to choose

  Go with tirzepatide if you want the most documented compound available. Extensive Phase III data, well-known titration schedules, predictable side effect profile. If you're starting your first incretin peptide, this is the safer bet in terms of data confidence.

  Go with retatrutide if the triple-agonist mechanism appeals to you. The added energy expenditure from glucagon is something no dual agonist can match. If liver fat is a specific concern, the early data on hepatic effects looks promising. Just know you're working with Phase II evidence for now.

  Some people run tirzepatide first, stabilize their weight, then switch to retatrutide for the next phase. Reasonable approach.

  Not sure which fits your situation? Reach out to us and we'll talk through the options.

  This article is for educational purposes. Peptides are intended for research use. Consult a healthcare professional before starting any protocol.